Scott Aaronson, MD

Chief Science Officer, Institute for Advanced Diagnostics and Therapeutics; Psychiatrist, The Retreat at Sheppard Pratt


  • Adult Psychiatry
  • Biological Psychiatry
  • Depression
  • Medication Management
  • Mood Disorders
  • Psychopharmacology
  • Transcranial Magnetic Stimulation (TMS)
  • Treatment-resistant Depression

Dr. Scott Aaronson is a thought leader in the areas of biological psychiatry, diagnosis, and the integration of somatic and psychological therapies. He is an adjunct professor of psychiatry at the University of Maryland School of Medicine, distinguished life fellow of the American Psychiatric Association, and is a fellow of the American College of Psychiatrists. Dr. Aaronson also serves on the boards of the American Society of Clinical Psychopharmacology and the Clinical TMS Society. 

In addition to his work at The Retreat, Dr. Aaronson is the director of clinical research programs at Sheppard Pratt, where he is the principal investigator for multiple studies on the development of therapies for mood and anxiety disorders. He has particularly been involved with the development of new strategies to alleviate the symptoms in treatment resistant mood disorders, and has published numerous articles on his research including pivotal studies in the use of devices—Transcranial Magnetic Stimulation (TMS) and Vagus Nerve Stimulation (VNS)—in the treatment of severe refractory mood disorders. Most recently, he was named the Chief Science Officer of the Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics, focused on the development of uses for psychedelic medications across the spectrum of psychiatric illness.